Phase I Study of Nivolumab and Ipilimumab Combined with Nintedanib in Advanced Non-Small Cell Lung Cancer

被引：2
|
作者：
Puri, S. [1 ]
Guadalupe, N. Rodriguez [2 ]
Niyongere, S. [3 ]
Boyle, T. [4 ]
Thapa, R. [5 ]
Chen, D. [5 ]
Noyes, D. [6 ]
Chatwal, M. [1 ]
Antonia, S. [7 ]
Gray, J. E. [7 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Hematol & Oncol, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[3] Univ Maryland, Sch Med, Dept Internal Med, Baltimore, MD 21201 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol & Thorac Oncol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Immunol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
tumor microenvironment; advanced non small cell lung cancer; Combination immunotherapy;
D O I：
10.1016/j.jtho.2019.08.1350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-06
引用
收藏
页码：S640 / S641
页数：2
相关论文
共 50 条
  • [1] The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer
    Puri, Sonam
    Tanvetyanon, Tawee
    Creelan, Ben C.
    Shafique, Michael Rahman
    Saltos, Andreas Nicholas
    Chiappori, Alberto
    Haura, Eric B.
    Thapa, Ram
    Chen, Dung-Tsa
    Boyle, Theresa A.
    Antonia, Scott Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer
    Puri, S.
    Tanvetyanon, T.
    Creelan, B.
    Shafique, M.
    Saltos, A.
    Chiappori, A.
    Haura, E.
    Thapa, R.
    Chen, D.
    Antonia, S.
    Gray, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S924 - S925
  • [3] Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC
    Puri, Sonam
    Niyongere, Sandrine
    Chatwal, Monica Sheila
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Noyes, David
    Antonia, Scott Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
    Kataoka, Shunichi
    Matsuno, Kei
    Sugano, Koji
    Takahashi, Kazuhisa
    BMJ CASE REPORTS, 2022, 15 (10)
  • [5] Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study
    Ulmeanu, Ruxandra
    Antohe, Ileana
    Anisie, Ecaterina
    Antoniu, Sabina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 165 - 167
  • [6] A Phase I Study of Enzastaurin Combined with Pemetrexed in Advanced Non-small Cell Lung Cancer
    Tanai, Chiharu
    Yamamoto, Nobuyuki
    Ohe, Yuichiro
    Takahashi, Toshiaki
    Kunitoh, Hideo
    Murakami, Haruyasu
    Yamamoto, Noboru
    Nakamura, Yukiko
    Nokihara, Hiroshi
    Shukuya, Takehito
    Baldwin, John R.
    Koshiji, Minori
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 1068 - 1074
  • [7] Clinical outcome of nivolumab and ipilimumab in untreated advanced non-small cell lung cancer patients
    Sugimoto, Akira
    Kaneda, Hiroyasu
    Nagamine, Hiroaki
    Nakahama, Kenji
    Ogawa, Koichi
    Matsumoto, Yoshiya
    Sawa, Kenji
    Tani, Yoko
    Mitsuoka, Shigeki
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    ANNALS OF ONCOLOGY, 2023, 34 : S1451 - S1451
  • [8] Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC)
    Okamoto, I.
    Miyazaki, M.
    Takeda, M.
    Azuma, K.
    Hayashi, H.
    Seto, T.
    Konishi, K.
    Sarashina, A.
    Kaiser, R.
    Nakagawa, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S830 - S831
  • [9] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, M. D.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S. -W.
    Carcereny Costa, E.
    Park, K.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Peters, S.
    Syrigos, K.
    Barlesi, F.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Rabindran, S. K.
    Kasinathan, R. S.
    Nathan, F. E.
    Ramalingam, S. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2020 - 2031
  • [10] Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma
    Diab, A.
    Abdel-Wahab, N.
    Bentebibel, S. E.
    Montazari, E. J.
    Spillson, C. A.
    Ekmekcioglu, S.
    Gao, J.
    Altan, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1456 - S1456
12345